Zdrowie i gospodarka · 24/09/2019

FDA Releases Final Guidance for ALS Drug Development

The Food and Drug Administration (FDA) has released a final guidance for the pharmaceutical industry on developing drugs to treat amyotrophic lateral sclerosis (ALS), a progressive neurological disorder. The guidance outlines the FDA's current thinking on clinical trial designs for ALS treatments, focusing on the main motor aspects of the disease, such as muscle weakness and shortened life expectancy.